Compare Coursera Inc (COUR) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Cytokinetics Inc — how do they compare? Coursera Inc trades at $5.57 (market cap $1.64B), while Cytokinetics Inc trades at $82.52 (market cap $11.12B). The key difference: Cytokinetics Inc is far larger — about 6.8× Coursera Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| COUR | CYTK | |
|---|---|---|
Market Cap | $1.64B | $11.12B |
Sector | Consumer Staples | Technology |
52-Week High | $12.70 | $87.26 |
52-Week Low | $5.09 | $33.23 |
Enterprise Value | $890.21M | $11.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.67, down 0.7% on the day, with technical indicators showing a bearish trend. The company reported Q1 2026 earnings of $0.07 per share, missing estimates of $0.09, but revenue growth remains positive, reaching $757.5 million in 2025. Recent news highlights the completion of the Udemy merger and a $500 million share repurchase program, while analyst sentiment is mixed with a consensus price target of $8.00.
The outlook for COUR is cautiously optimistic, driven by potential synergies from the Udemy merger and steady revenue growth, though profitability challenges and competitive pressures pose risks. With a 52.94% buy rating from analysts and a 38.5% upside to the consensus target, the stock offers growth potential, but investors should monitor execution on cost management and integration success.
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
